Review

Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness

Myrofora Panagi1, Pampina Pilavaki2, Anastasia Constantinidou2,3,4 and Triantafyllos Stylianopoulos1,5

1. Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus.
2. Medical School, University of Cyprus, Nicosia, Cyprus.
3. Bank of Cyprus Oncology Centre, Nicosia, Cyprus.
4. Cyprus Cancer Research Institute, Nicosia, Cyprus.

Corresponding authors: Anastasia Constantinidou, MD, Ph.D., email:constantinidou.anastasia@ucy.ac.cy and Triantafyllos Stylianopoulos, Ph.D., email:tstylian@ucy.ac.cy

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

See http://ivyspring.com/terms for full terms and conditions.

Received: 2022.03.11; Accepted: 2022.07.21; Published: 2022.08.15

Abstract

Sarcomas are uncommon malignancies of mesenchymal origin that can arise throughout the human lifespan, at any part of the body. Surgery remains the optimal treatment modality whilst response to conventional treatments, such as chemotherapy and radiation, is minimal. Immunotherapy has emerged as a novel approach to treat different cancer types but efficacy in soft tissue sarcoma and bone sarcoma is limited to distinct subtypes. Growing evidence shows that cancer-stroma cell interactions and their microenvironment play a key role in the effectiveness of immunotherapy. However, the pathophysiological and immunological properties of the sarcoma tumor microenvironment in relation to immunotherapy advances, has not been broadly reviewed. Here, we provide an up-to-date overview of the different immunotherapy modalities as potential treatments for sarcoma, identify barriers posed by the sarcoma microenvironment to immunotherapy, highlight their relevance for impeding effectiveness, and suggest mechanisms to overcome these barriers.

Key words: tumor microenvironment, immunosuppression, hypoxia, tumor normalization, mechanotherapeutics

Introduction

Sarcomas are a group of rare and highly heterogeneous malignancies encompassing more than 100 distinct histological subtypes [1, 2]. They can be broadly divided into two categories: soft tissue sarcomas which develop from fat, muscle, blood vessels, nerves, and other connective tissues, and bone sarcomas. The overall incidence rate for soft tissue sarcoma ranges between 4 and 5 cases per 100,000/year, with liposarcoma and leiomyosarcoma being the most common subtypes [3]. Bone sarcoma is less prevalent with an estimated incidence of 0.8 cases per 100,000/year, with osteosarcomas being the most common, followed by conventional chondrosarcoma and Ewing sarcoma [4].

Despite recent advances in cancer research, developments in sarcoma treatment have been slow. For localized disease, the primary treatment option is surgical resection of the tumor with adjuvant or neoadjuvant radiation therapy in selected cases. Localized soft tissue sarcoma and bone sarcoma patients have a 5-year disease free survival rate >80 % and 70 %, respectively. However, disease relapse occurs in more than half of the patients, often with the development of distant metastasis. Advanced disease cases are extremely challenging to treat. Conventional chemotherapeutics do not lead to durable responses or cure and patients may experience substantial toxicities. The standard therapy for metastatic disease is primarily structured around anthracycline-based chemotherapy [3, 4], while other agents including dacarbazine [5], gemcitabine/docetaxel [6], ifosfamide [7], trabectedin [8], pazobanib [9] and eribulin [10] might also be used. The median overall survival of patients with metastatic disease ranges from 12 to 18 months [11, 12]. Therefore, with limited success of conventional chemotherapy for sarcoma in clinical
practice, there is a high unmet need to develop novel therapeutic strategies with improved efficacy and safety for these patients.

A flurry of new research is now exploring the role of immunotherapy in sarcoma. Unlike chemotherapy, which directly kills cancer cells, immunotherapy relies on stimulating the natural defenses of the host immune system to attack malignant cells. Modalities of immunotherapy can be grouped in the following clusters: immune checkpoint inhibitors (ICIs), adoptive cell therapy (ACT), cancer vaccines and in situ vaccination (ISV) including oncolytic virotherapy. Indeed, there is a large number of clinical trials for the use of immunotherapy in patients with sarcoma, but none of them has led to approval yet. The absence of dramatic immunotherapeutic responses in most cases has been attributed to a variety of factors, including barriers imposed by the tumor microenvironment that among others hinder the delivery of the immunotherapeutic agents and cause immunosuppression. The current review i) summarizes current knowledge on immunotherapy application in soft tissue and bone sarcoma in the clinical and preclinical setting over the last decade, ii) discusses the barriers posed by the sarcoma microenvironment hindering immunotherapy efficacy and iii) provides an overview of potential strategies that are tailored to overcome these barriers.

**Immunotherapeutic strategies in clinical cancer treatment**

**Immune checkpoint inhibition**

Immune checkpoints have evolved to act as gatekeepers of immune responses by suppressing inflammation-induced tissue damage and autoimmunity. However, cancer cells hijack the immune checkpoint signaling by upregulating inhibitory immunoreceptors (e.g., PD-1, CTLA-4, LAG3, TIM3, TIGIT and BTLA) on immune cell surface, capable of suppressing both antigen and co-stimulatory signaling upon ligand engagement [13] and thus, allowing tumor-cells to escape surveillance from both the adaptive and innate immune system. Monoclonal antibodies directed against immune checkpoint molecules, known as immune checkpoint inhibitors (ICIs), comprise the most advanced paradigm of immunotherapy in the clinical setting, managing to prolong overall survival of patients with melanoma [14-16], triple negative breast cancer [17], non-small cell lung cancer [18], renal cell cancer, Hodgkin’s lymphoma, urothelial cancer and mismatch repair deficient /microsatellite instability high (MSI-H) tumors [19-23]. The currently approved ICIs by FDA inhibit the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4, e.g., ipilimumab, tremelimumab), the programmed cell death protein 1 (PD-1, e.g., nivolumab, pembrolizumab) and the programmed cell death ligand (PD-L1, e.g., atezolizumab, avelumab, durvalumab).

With regards to sarcoma patients, blockade of the PD-1/PD-L1 axis has been promising for specific histological subtypes. A completed phase 2 clinical trial, SARC028 (NCT02301039, Table 1) investigating the use of pembrolizumab for the treatment of advanced sarcoma, demonstrated an objective response in seven out of the forty patients (18%) with soft-tissue sarcoma and partial response in two of the forty patients (5%) with bone sarcoma. Response was determined by investigators using RECIST version 1.1. In the soft tissue sarcoma patients’ cohort, the benefit was limited to four out of ten patients with undifferentiated pleomorphic sarcoma, two out of ten patients with dedifferentiated liposarcomas and one out of ten patients with synovial sarcoma. No clinical benefit was observed in leiomyosarcoma patients. In the bone sarcoma cohort, one out of twenty two patients with osteosarcoma and one out of five patients with chondrosarcoma had an objective response, while none of the thirteen patients with Ewing sarcoma responded to immune checkpoint inhibition. Notably, a positive correlation between PD-L1 expression and therapeutic outcome was established in three patients with undifferentiated pleomorphic sarcoma. Of the three patients, one had a complete response and the other had a partial response. Consistent with previous studies [24, 25], undifferentiated pleomorphic sarcoma patients evaluated for response by RECIST 1.1 criteria had higher numbers of activated T cells, increased PD-L1 expression on immunosuppressive tumor associated macrophages (TAMs) and more regulatory T cells (Tregs), compared to non-responders prior to PD-L1 inhibition [26]. These findings suggest that undifferentiated pleomorphic sarcoma may fit the model of an inflamed tumor responding to PD-L1 inhibition. Moreover, Alliance A091401 (NCT02500797, Table 1), is another phase 2 clinical trial investigating the use of nivolumab versus nivolumab plus ipilimumab in patients with sarcoma (soft tissue or bone sarcoma). Confirmed responses defined as complete or partial response by RECIST 1.1 were reported in two (5%, one with alveolar soft part sarcoma and one with non-uterine leiomyosarcoma) out of the thirty eight patients in the combination group, particularly in those diagnosed with undifferentiated pleomorphic sarcoma, leiomyosarcoma, myxofibrosarcoma, malignant fibrous
histiocytoma and angiosarcoma. Interestingly, the proportion of confirmed objective responses in the combination treatment group is comparable to that obtained with front-line standard chemotherapy, thus highlighting the potential of nivolumab plus ipilimumab as a first-line therapy alternative.

Although no treatment-related deaths were documented, adverse effects associated to immunotherapy including anemia, decreased lymphocyte count, dehydration and other were reported in both treatment arms. Alliance was the first study to investigate the combination of checkpoint inhibitors and demonstrated promising efficacy results in certain sarcoma subtypes [27]. The rationale behind this combination was based on ipilimumab’s effect to increase T cell activation and thus, allow nivolumab to augment anti-tumor T cell responses. Consistent with the SARC028 study, expression of genes implicated in antigen presentation and T cell infiltration was higher in undifferentiated pleomorphic sarcoma and leiomyosarcoma compared to synovial sarcoma and liposarcoma. Overall, discrepancy to ICI efficacy seems to rely on the pre-existing immunogenicity of the tumor microenvironment (TME). However, the small number of biopsies collected during, before and throughout treatment and the subsequent characterization of TME composition and infiltration of lymphocytes among responders, limit the comprehensive analysis of biomarkers. Determination of baseline antitumor immunity of responders before treatment is required to understand the infrequent responses and mechanisms of resistance in tumor subtypes, in which rational combination therapies could be considered. Accordingly, current clinical findings postulate that a TME deprived of infiltrating lymphocytes is less likely to benefit from such a treatment modality [28]. Other factors that impact ICI therapy include checkpoint expression status, tumor microsatellite instability (MSI) and tumor mutational burden [29-32]. A summary of clinical trials employing ICIs for sarcoma are listed in Table 1.

Adoptive cell therapy

ACT, also known as cellular immunotherapy, comprises the intravenous transfer of either tumor-resident or genetically modified blood-derived immune cells into patients to augment antitumor immune responses. The most widespread form of ACT is T cell based and can be classified into (i) ACT with tumor-infiltrating lymphocytes (TIL) and (ii) ACT with genetically engineered T cell receptor (TCR) or synthetic chimeric antigen receptor (CAR) targeting tumor specific antigens [33, 34]. A consistent success of TIL therapy has been demonstrated only in melanoma patients, whereas production and reactivity of TILs from other solid tumor types has led to variable antitumor responses, presumably due to the highly heterogenic mutational and neoantigen load [34-36]. Administration of TIL therapy combined with adjuvant chemotherapy was found to significantly prolong the survival of osteosarcoma patients with a poor response to neoadjuvant chemotherapy, compared to the patients receiving adjuvant chemotherapy. In addition, univariate and multivariate analyses indicated that a greater number of TILs transfused as an independent prognostic factor for both the median disease-free survival and overall survival [37].

With respect to TCR-modified cell therapy, an affinity-enhanced TCR recognizing the cancer testis antigen, NY-ESO-1, reported encouraging results for the treatment of metastatic synovial sarcoma (Table 1), confirming antitumor responses in half of the patients [38]. Further investigation showed that the response was associated with modest increase in intratumoral leukocyte infiltration and minimal infiltration of CD163+ TAMs, compared to the pre-infusion state [39].

Conversely to TCR-modified T cells, CAR T cells can induce conventional activation signals from TCRs in an MHC-independent manner. Notably, CAR T therapy is applied in hematological neoplasms producing remarkable and durable responses, while its application in solid tumors has been rather unsatisfactory [40]. Evaluation of safety and efficacy of tumor-directed T cells in sarcoma patients is in the early stages of clinical development. To date, T cells expressing a HER2-specific chimeric antigen receptor with a CD28ζ signaling domain (HER2-CAR T cells) have been evaluated in a phase 1/2 clinical study in patients with HER2 positive sarcomas confirming that these cells can persist for six weeks without evident toxicities (Table 1). No follow up of this study or additional clinical documentation regarding CAR T cell therapy has been reported since then [41]. Potential barriers include the insufficient T cell penetration into solid masses due to physical obstacles, the lack of targetable antigens solely expressed on tumor cells and the limited CAR T cell persistence after infusion and homing of potent immunosuppressive cells that tender T cells dysfunction in the TME [42]. An alternative and less complex approach of ACT is the CAR-NK cell therapy [43, 44]. Clinical success of CAR-NK cell therapy has been initially demonstrated in hematological cancers [45, 46] and currently is being evaluated in solid malignancies including sarcoma (NCT02100891).
**Cancer vaccines**

Cancer vaccines involve the exogenous administration of selected tumor associated antigens (TAA) combined with adjuvants. The ultimate goal is to provoke an adaptive T cell response capable of eradicating residual tumor and establishing a lasting antitumor memory in the absence of adverse effects and non-specific reactions. Traditionally, antigens can be delivered in the form of DNA, RNA and peptide itself, or via autologous dendritic cells (DCs). Administration of autologous DCs matured with autologous tumor lysate and keyhole limpet hemocyanin was found to improve clinical outcome in patients diagnosed with Ewing/rhabdomyosarcoma, whereas other histological subtypes failed to respond. Of note, T cell responses to autologous tumor lysate were identified in more than half of immunotherapy recipients, in agreement with a higher survival, while an enhanced immune reconstitution was reported after addition of interleukin 7 (IL7) [47]. In line with these results, vaccination of metastatic Ewing sarcoma patients with Vigil vaccine (GMCSF/bi-shRNAfurin DNA-transfected autologous tumor immunotherapy) resulted in improved overall survival compared to the unvaccinated group [48]. On the contrary, autologous tumor lysate pulsed dendritic cell vaccination of patients with bone and soft tissue sarcoma showed minimal clinical effectiveness, although the reported increased levels in IFNγ and IL12 post-vaccination [49, 50]. Representative clinical trials using cancer vaccines for soft tissue and bone sarcomas are listed in Table 1.

**In situ vaccines**

iSVs comprise a novel arm of cancer immunotherapy. As opposed to conventional

### Table 1: Selected completed immunotherapy clinical trials for Soft tissue sarcomas and Bone sarcomas.

<table>
<thead>
<tr>
<th>Immunotherapy Intervention</th>
<th>Study</th>
<th>Disease</th>
<th>Response rate</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ICIs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>Phase 2 (NCT02301039) [26]</td>
<td>Advanced STS and BS</td>
<td>-18% in STS, 40% in UPS, 20% in LPS, 10% in SS, 0% in LMS, 5% in BS, 5% in OS, 20% in CHS, 0% in Ew5</td>
<td>mPFS: 19.1 months in STS mPFS: 17.8 months in BS</td>
</tr>
<tr>
<td>Pembrolizumab + cyclophosphamide</td>
<td>Phase 2 (NCT02406781) [163]</td>
<td>Advanced STS</td>
<td>-0% in LMS, 0% in UPS, 14.3% in other, 11.1% in GIST</td>
<td>mPFS: 1.4 months in LMS, UPS, other sarcomas and GIST mOS: 9.2 months in LMS, 5.6 months in UPS, 7.1 months in other sarcomas -not reached in GIST</td>
</tr>
<tr>
<td>Nivolumab +/- Ipilimumab</td>
<td>Phase 2 (NCT02500797) [27]</td>
<td>Metastatic STS</td>
<td>-Nivolumab group: 8% (ASPS, non-uterine LMS, sarcoma NOS) -Nivolumab + Ipilimumab group: 15% (uterine LMS, non-uterine LMS, UPS/MEH, angiosarcoma, myxofibrosarcoma)</td>
<td>-Nivolumab mO: 17.1 weeks</td>
</tr>
<tr>
<td>T-VEC + pembrolizumab</td>
<td>Phase 2 (NCT0306978) [54]</td>
<td>Advanced or metastatic sarcoma (LMS, angiosarcomas, UPS, undifferentiated or unclassified sarcoma, other histologic subtypes)</td>
<td>-PR: 35% (7 patients) -SD: 35% (7 patients) -PD: 30% (6 patients)</td>
<td>mPFS: 17.1 weeks</td>
</tr>
<tr>
<td>Nivolumab + sunitinib</td>
<td>Phase 1b/2 (NCT0327924) [367]</td>
<td>Advanced STS</td>
<td>-ORR: 21%</td>
<td>mPFS: 5.6 months for central and 6 months for local assessment mOS: 24 months</td>
</tr>
<tr>
<td><strong>ACT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HER2-specific CAR T cell</td>
<td>Phase 1/2 (NCT0092044) [41]</td>
<td>Refractory or recurrent metastatic HER2 positive sarcomas</td>
<td>-PR: 5.8% (1 patient) -SD: 23.5% (4 patients) -PD: 70.6% (12 patients)</td>
<td>mPFS: 10.1 mOS: 10.3 months</td>
</tr>
<tr>
<td>NY-ESO-1 SPEAR T cells</td>
<td>Phase 1/2 (NCT01343043) [39]</td>
<td>ESO-1 positive SS</td>
<td>-CR: 2.4% (1 patient) -PR: 33.4% (14 patients) -SD: 57.1% (24 patients) -PD: 7.1% (3 patients)</td>
<td>mPFS: 17.1 weeks</td>
</tr>
<tr>
<td><strong>Cancer Vaccines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>autologous lymphocyte infusion plus KLH pulsed dendritic cell vaccine +/- rHIL7</td>
<td>Phase 2 (NCT00923531) [47]</td>
<td>Metastatic or recurrent Ew5, RMS, D8RCT, SS and undifferentiated sarcoma</td>
<td>-5-year OS: 63% for Ew5/RMS and 0% for other sarcomas -5-year PFS: 40% for Ew5/RMS and 0% for other sarcomas</td>
<td></td>
</tr>
<tr>
<td>Autologous tumor lysate pulsed DCs</td>
<td>Phase 1/2 [49]</td>
<td>Metastatic or recurrent BS and STS</td>
<td>-PR: 2.9% (1 patient) -SD: 17.1% (6 patients) -PD: 80% (28 patients)</td>
<td>-3-year OS rate: 42.3% -3-year PFS rate: 2.9%</td>
</tr>
<tr>
<td>CMX005 vaccine</td>
<td>Phase 1b [230]</td>
<td>NY-ESO-1 positive locally advanced, relapsed, or metastatic sarcomas</td>
<td>-DCR: 61.9%</td>
<td>OS: 26.2 months</td>
</tr>
</tbody>
</table>

**Vaccines**

Cancer vaccines 

Vaccines involve the exogenous administration of selected tumor associated antigens (TAA) combined with adjuvants. The ultimate goal is to provoke an adaptive T cell response capable of eradicating residual tumor and establishing a lasting antitumor memory in the absence of adverse effects and non-specific reactions. Traditionally, antigens can be delivered in the form of DNA, RNA and peptide itself, or via autologous dendritic cells (DCs). Administration of autologous DCs matured with autologous tumor lysate and keyhole limpet hemocyanin was found to improve clinical outcome in patients diagnosed with Ewing/rhabdomyosarcoma, whereas other histological subtypes failed to respond. Of note, T cell responses to autologous tumor lysate were identified in more than half of immunotherapy recipients, in agreement with a higher survival, while an enhanced immune reconstitution was reported after addition of interleukin 7 (IL7) [47]. In line with these results, vaccination of metastatic Ewing sarcoma patients with Vigil vaccine (GMCSF/bi-shRNAfurin DNA-transfected autologous tumor immunotherapy) resulted in improved overall survival compared to the unvaccinated group [48]. On the contrary, autologous tumor lysate pulsed dendritic cell vaccination of patients with bone and soft tissue sarcoma showed minimal clinical effectiveness, although the reported increased levels in IFNγ and IL12 post-vaccination [49, 50]. Representative clinical trials using cancer vaccines for soft tissue and bone sarcomas are listed in Table 1.

**In situ vaccines**

iSVs comprise a novel arm of cancer immunotherapy. As opposed to conventional
vaccines, iSVs are antigen-agnostic agents having the ability to mount endogenous antitumor responses, directly or indirectly, by "generating" a vaccine within the TME following sourcing of antigens from dead or dying tumor cells. The mechanisms of action of iSVs mainly rely on the activation of innate immune pattern recognition receptors (e.g., TLRs) and stimulator of interferon genes (STING) protein [51]. The antitumor efficacy of iSV agents as monotherapy or combination therapy is now evaluated in different solid tumors, including sarcomas. Some intrinsic examples of these studies are the combination of a Poly-ICLC agonist for RIG-I/MDA5 and TLR3 with anti-PD-1 or anti-PD-L1 treatment (NCT02423863) and the combination of TLR4 agonist G100 with anti-PD-1 plus metronomic cyclophosphamide in patients with advanced sarcomas (NCT02406781).

Another class of recently introduced iSV agents are the oncolytic viruses. Genetically or chemically modified oncolytic viruses expressing immunomodulators specifically infect and replicate within cancer cells inducing immunogenic cell death and consequent release of TAA and neoantigens. This process results in local priming of the immune system (recruitment of DCs and NK cells to the tumor site), leading to an effective rejection of both virus-injected and distant tumors [52]. To date, talimogene laherparepvec (T-vec), a genetically modified GM-CSF-expressing herpes simplex virus, is the first and only oncolytic immunotherapy approved by the FDA for the treatment of advanced melanoma [53]. A phase 2 clinical trial investigating the efficacy of T-vec with pembrolizumab for sarcoma treatment demonstrated a benefit only in specific subtypes. Specifically, partial responses were seen in patients with cutaneous angiosarcoma of head and neck, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, epithelioid sarcoma and in one case with unclassified sarcoma. Importantly, the immune microenvironment of responders correlated with an upregulation of PD-L1 expression and higher TIL content (NCT03069378, Table 1) [54].

Lessons from preclinical studies

Despite the rapid advances made in the field, immunotherapy for sarcoma treatment is still in its infancy. The rarity, heterogeneity and complexity of these mesenchymal malignancies create challenges around diagnosis and treatment decisions. Thus, significant attention should be paid during trial design and interpretation of results. An approach to improve clinical trial design and eliminate uncertainties about the treatment effect in such rare diseases is the consideration of comprehensive preclinical evidence that strongly supports the effectiveness of a particular therapeutic intervention for a specific sarcoma subtype.

Landscape of immunotherapy in soft tissue sarcoma

Fibrosarcoma is the most frequently employed tumor model in the preclinical setting with regards to soft tissue sarcoma immunotherapy (Figure 1). Multiple immunotherapy approaches have been investigated with ICI and cancer vaccines being the most extensively studied, often in combination with adjuvants (Table 2, Table S1). An intrinsic example is the dual targeting of co-inhibitory CTLA-4 and costimulatory OX40 signaling pathways. Ligation of the TNF receptor family OX40 (CD134) with the agonist anti-OX40 led to enhanced antitumor immunity by augmenting effector T cell differentiation and suppressing the activity of Tregs [55]. With reference to tumor specific antibody-cytokine fusion proteins, L19 antibody (targeting fibronectin)-mIL12 construct was found to induce a strong antitumor effect against fibrosarcoma tumors only after combination with PD-1 inhibition. Neither PD-1 or CTLA-4 monotherapy or anti-CTLA-4-L19-mIL12 combination therapy had any impact on tumor control [56]. Another promising therapeutic intervention implicates DC-based vaccination and targeting of HSP90 via the 17-DMAG inhibitor. Binding of 17-DMAG to HSP90 results in the degradation of the HSP90 client protein EphA2, a receptor tyrosine kinase which is highly upregulated in a variety of cancers and correlates with poor prognosis and metastasis [57]. Proteasomal degradation of EphA2 promoted MHC class I presentation of the derivative peptide epitopes and their subsequent recognition by specific CD8+ T cells leading to sarcoma regression. Nevertheless, when coordinated with vaccination, 17-DMAG co-administration yielded superior antitumor efficacy capable of rendering animals free of disease, as opposed to treatment with either single modality [58]. In a different study, fibrosarcoma tumors refractory to doxorubicin chemotherapy partly due to weak expression of nuclear HMGB1, exhibited higher response rates in the presence of the synthetic TLR4 agonist, Dendrophilin. The synergistic antitumor effects were attributed to the enhanced DC-dependent T cell priming mediated by restoration of the immunogenicity of dying tumor cells and increased intratumoral accumulation of IFNγ+ lymphocytes [59].
Figure 1: Landscape of immunotherapy application in sarcoma treatment. Visualization of the number of studies performed from 2011 to 2021 for each sarcoma subtype, assessing the efficacy of different immunotherapy modalities in the preclinical setting. The circle diameter indicates the relative proportion of preclinical studies identified. Combination circle includes combinations between two or more immunotherapy modalities or combinations with chemotherapeutics or radiation therapy. The data included in this figure are listed in Tables 2 and 3 and Tables S1 and S2. FB, fibrosarcoma; DDLPS, dedifferentiated liposarcoma; LPS, liposarcoma; RMS, rhabdomyosarcoma; LMS, leiomyosarcoma; SS, synovial sarcoma; UPS, undifferentiated pleomorphic sarcoma; Other STS, undefined type of STS; EwS, Ewing sarcoma; BS, bone sarcoma; CHS, chondrosarcoma; ICI, immune checkpoint inhibitors; ACT, adoptive cell therapy; iSVs, in situ vaccines

Table 2: Preclinical Studies for Soft Tissue Sarcoma Immunotherapy.

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Monotherapy</th>
<th>ICIs</th>
<th>ACT</th>
<th>Oncolytic viruses</th>
<th>Cancer Vaccines</th>
<th>In situ vaccines</th>
<th>Immunotherapy + iSVs + CT/RT</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICIs</td>
<td>FB [231]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FB [188, 189]</td>
</tr>
<tr>
<td></td>
<td>DDLPS [77]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACT</td>
<td>FB [232]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FB [286, 287]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LPS [65]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>UPS [68]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncolytic viruses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer Vaccines</td>
<td>FB [234-242]</td>
<td>LMS [67]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In situ vaccines</td>
<td>FB [197, 198, 245-251]</td>
<td>LPS [78]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FB [55, 56, 69, 162, 253-255]</td>
<td>FB [257]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LMS [66]</td>
<td>RMS [62, 63]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>F244 MCA [252]</td>
<td>1956 sarcoma [256]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT/RT</td>
<td>FB [59, 264-266]</td>
<td>FB [267, 268]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Mimicking the clinical scenario, the efficacy of ICI in rhabdomyosarcoma is yet to be determined. Nevertheless, alternative strategies have been developed including ACT using NK [60] or genetically engineered T cells [61], DC-based vaccination [62, 63] or virotherapy [64], all administered with various iSVs. A more recent study assessed and confirmed the antitumor efficacy of CAR-modified cytokine-induced killer cells as an alternative type of effector cells [65]. Cytokine-induced killer cells are a heterogeneous population of effector NKT cells which can be easily expanded from peripheral blood mononuclear cells and subjected to genetic engineering to express CARs. Accordingly, administration of CAR cytokine-induced killer cells directed against the TAA ERBB2 led to a complete inhibition of initial tumor load and microscopic clearance of tumors mediated by enhanced accumulation of NK and NKT cell subpopulations in disseminated rhabdomyosarcoma. On the contrary, non-targeted cytokine-induced killer cell therapy exhibited a partial tumor inhibition [65]. Therefore, the dual role of cytokine-induced killer cells as targeted killers and modulators of innate immunity in
parallel with the diverse T and NK cell receptor specificities, make them an attractive platform with considerable potential to improve the clinical outcome of sarcoma patients.

Leiomyosarcomas, liposarcomas and undifferentiated pleomorphic sarcomas are among the most common soft tissue sarcomas and yet, the less studied in the preclinical setting, at least in the context of immunotherapy [1]. An early attempt to harness the host’s immune system to cure aggressive metastatic leiomyosarcoma involved the targeting of CD47 protein. Mice receiving anti-CD47 treatment experienced significant tumor size reduction and regression of metastatic disease mainly via stimulating macrophage dependent phagocytosis [66]. A later study evaluated the efficacy of oncolytic immunotherapy using a serotype chimeric oncolytic adenovirus coding for the GM-CSF, Ad5/3-D24-GMCSF. Ad5/3-D24-GMCSF treatment not only circumvent off-target toxicity associated with the systemic use of GM-CSF, but also exhibited a potent antitumor activity which was further validated in soft tissue sarcoma patients [67].

Initial preclinical work on undifferentiated pleomorphic sarcoma exploited the antitumor activity of patient derived cytokine-induced killer cells demonstrating that intravenous infusions of cytokine-induced killer cells could cause a significant delay of tumor growth and facilitate killing of putative sarcoma cancer stem cells [68]. Later, new evidence emerged showing that inhibition of retinoic acid signaling synergizes with anti-PD-1 treatment increasing the frequency of immunostimulatory antigen presenting cells (APCs) and engendering tumor regression. Consistent with its pro-tumor activities, the pertinent study showed that T cell-derived IL13 can induce retinoic acid production by sarcoma cells which in turn inhibits tumor monocyte differentiation into DCs and promotes generation of immunosuppressive macrophages [69]. Retinoic acid plays a crucial role in shaping the tumor immune microenvironment acting both as an anti- and pro-tumor agent [70]. While many studies have reported that retinoic acid supports immune tolerance via suppressing the differentiation of monocyte derived DCs [71], promoting the differentiation of Tregs [72] and Arg1 producing anti-inflammatory macrophages [73, 74], others have reached the opposite conclusion [75, 76]. As such, a more thorough investigation is required to support the antitumor effects of retinoic acid signaling inhibition across soft tissue sarcoma histological subtypes.

Preclinical studies on animal models of liposarcoma have just commenced. To date, there are only a few available studies both exploring the antitumor efficacy of PD-1 inhibition as a monotherapy [77] and its combinatorial effect with the oncolytic vaccinia virus (GLV-1h68) [78], in a model of dedifferentiated liposarcoma and liposarcoma (of unspecified histological subtype), respectively. Notably, anti-PD-1 treatment significantly slowed tumor growth by promoting accumulation and activity of CD8+ T cells and NK cells [77]. Considering dual treatment, pretreatment with GLV-1h68, delivered using isolated limb perfusion (viral ILP), potentiated antitumor responses of PD-1 blockade, which had a minimal efficacy as a single modality. Moreover, when performed prior to compartmentectomy and radiotherapy, combined treatment prevented both local and distant relapse [78].

Synovial sarcoma is another example of most common and refractory to treatment soft tissue sarcomas. Surgical resection, accompanied by radiation and/or chemotherapy, has shown to be effective only during early stages of the disease while no successful therapies have been established for advanced synovial sarcoma, so far. In addition, the application of ICI in the synovial sarcoma treatment as part of clinical trials has not been successful (NCT02301039, NCT02304458). Nevertheless, emerging preclinical work reported that targeting of FZD10 combined with radioimmunotherapy exhibited a potent antitumor activity against xenograft tumors. Specifically, it was shown that labeling of anti-FZD10 antibody with α-emitting radionuclides is superior to β-emitters labeling with no apparent systemic toxicities. FZD10 is highly expressed in synovial sarcoma and serves as a putative receptor of Wnt signaling and thus, a promising target for iSV [79].

Landscape of immunotherapy in bone sarcoma

ICI is currently the most prominent immunotherapy modality for osteosarcoma treatment in clinical practice. Although the clinical benefit from ICI alone is rather sporadic, preclinical studies indicate that combinations with other modalities of immunotherapy can significantly potentiate their antitumor responses (Table 3, Table S2). An intrinsic example is the combination of PD-1 blockade with the CXCR4 antagonist, AMD3100, which facilitates SDF-1/CXCR4 signaling inhibition. CXCR4 activation transmits signals that promote survival and accumulation of myeloid-derived suppressor cells (MDSCs) in osteosarcoma microenvironment and inhibiting cytotoxic T lymphocyte (CTL) trafficking and function and thus, blunting the response to anti-PD-1 therapy. ICI alone does not affect tumor growth and CXCR4 inhibition only modestly reduces
its size. However, anti-PD-1 and AMD3100 co-administration synergistically expands infiltrating CTLs, enhances tumor growth control and prolongs survival [80]. Similarly to CXCR4 antagonist, a variety of iSVs have reported synergistic effects in the context of NK and T cell based ACT [81-85], DC vaccination [86, 87] and chemotherapy [88] or radiotherapy [89]. Regarding cancer vaccines, CTLA-4 blockade was found to cooperate with cryotreated tumor lysate-pulsed DC vaccine in a primary tumor control to prevent the outgrowth of lung metastasis by reducing levels of Tregs and increasing infiltration of cytotoxic CD8+ lymphocytes inside the metastatic tumor [90]. A more recent study has exploited the combination of either PD-1 or PD-L1 blockade with adoptive transfer of T cells armed with anti-GD2-BsAb (GD2-EATs) or anti-HER2-BsAb (HER2-EATs) [91]. Both GD2 and HER2 are upregulated in osteosarcoma making them suitable targets. Interestingly, anti-PD-L1 combination treatment enhanced BsAb-armed T cell function and targets. Interestingly, anti-PD-L1 combination might be partially explained by the upregulation of osteosarcoma setting [85]. Moreover, a novel upcoming combination for the treatment of pediatric Ewing sarcoma is that of activated and expanded NK cells with virotherapy. In vitro evidence indicated that co-culture of MeV-infected sarcoma cells with NK cells stimulated the release of GZMA/B, perforin and granulysin resulting in higher oncolysis rates when compared to the respective monotherapies [98].

Unlike osteosarcoma and Ewing sarcoma, preclinical evaluation of immunotherapy in chondrosarcoma is restricted to a single study. Consistent with the clinical application of zoledronate (ZOL), a nitrogen-containing bisphosphonate sensitizing tumors to Vγ9Vδ2 T cell-mediated cytotoxicity, Sun et al. showed that weekly intravenous ZOL administration improved Vγ9Vδ2 T cell cytotoxicity in a TCR-dependent and via perforin-mediated mechanisms, resulting in potent antitumor effects [99, 100].

**Barriers to immunotherapy for soft tissue and bone sarcoma**

The intrinsically heterogeneous nature of sarcomas and the complexity of the TME have a decisive role in their behavior and response to treatment. In the TME, tumor cells coexist with heterotypic cell populations including immune cells, endothelial cells, pericytes, cancer associated fibroblasts (CAFs), mesenchymal stem cells (MSCs) and nerve fibers, with which they communicate via direct cellular contact and an array of paracrine signals. Communication between cancer cells and stroma is also modulated by extracellular matrix components and the microbiome.

---

**Table 3: Preclinical Studies for Bone Sarcoma Immunotherapy.**

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Monotherapy</th>
<th>ICIs</th>
<th>ACT</th>
<th>Oncolytic viruses</th>
<th>Cancer Vaccines</th>
<th>iSVs</th>
<th>Immunotherapy + iSVs + CT/RT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ICIs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACT</td>
<td>OS [269-272]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>OS [273-278]</td>
<td>OS [91]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EwS [274, 279-284]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oncolytic viruses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OS [285]</td>
<td>OS [286]</td>
<td>EwS [98]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cancer vaccines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OS [241, 287-291]</td>
<td>OS [90, 292]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>iSVs</strong></td>
<td>OS [293-313]</td>
<td>OS [80, 314, 315]</td>
<td>OS [82-85]</td>
<td>EwS [85, 316]</td>
<td>CHS [100]</td>
<td>OS [86, 87]</td>
<td></td>
</tr>
</tbody>
</table>


OS, osteosarcoma; EwS, Ewing sarcoma; CHS, chondrosarcoma; CT, chemotherapy; RT, radiotherapy; ICIs, immune checkpoint inhibitors; ACT, adoptive cell therapy; iSVs, in situ vaccines

---

**Theranostics** 2022, Vol. 12, Issue 14

6113
Different immune cell populations coexist within the TME. Based on the spatial distribution of CD8+ T lymphocytes in the TME, solid tumors are generally classified into highly inflamed- “hot” and non-inflamed- “cold”. “Cold” tumors can be further subdivided into immune desert or immune excluded (Figure 2A). In “hot” tumors, T cells are present but inactive or exhausted. Immune desert tumors lack T cell penetration while immune excluded have the T cells accumulated at the invasive margins and absent from the tumor core [101, 102]. Apart from TILs, additional features of the TME such as the expression of PD-1 receptor in T cells and PD-L1 in tumor cells and macrophages, degree of tumor mutational burden and the presence of a pre-existing antitumor immune response have been described as characteristics of “hot” tumors, related with good response to ICI. In fact, different studies in carcinomas demonstrate the role of TILs as biomarkers of response to ICI [103-105], ATC [106] and DC vaccination [107]. However, such correlations have not been clearly established across sarcoma subtypes, instead more effort should be made to identify specific signatures of the TME among responders and achieve the level of evidence that defines them as “predictive biomarkers”.

For osteosarcoma, different studies have demonstrated that higher numbers of infiltrating CD8+ than Foxp3+ T cells separate survivors from non-survivors [108]. On the contrary, the presence of macrophages in TME is rather more complex and depends on the shifts between the immunostimulatory M1 and the immune-suppressive M2 phenotype. In osteosarcoma, CD163+ M2 macrophages promote angiogenesis, and metastasis by mediating cancer cell extravasation and suppressing TIL homing [109-111]. Sarcomas driven by reciprocal fusion oncoproteins, like Ewing sarcoma exhibit a “cold” microenvironment with low PD-L1 expression [112]. TILs and DCs occur rarely whereas immunosuppressive cells of the myeloid lineage like macrophages predominate at the tumor site and correlate with poorer overall survival [113].

With regards to soft tissue sarcoma, TIL abundance correlates with improved prognosis in high-grade undifferentiated pleomorphic sarcoma, gastrointestinal stromal tumor, cutaneous angiosarcoma, leiomyosarcoma and synovial sarcoma [114]. Adding to this, the high expression of PD-1 and PD-L1 among lymphocytes reported across various subtypes was found to associate with higher tumor grading and lower survival [24, 25, 115]. Macrophage infiltration is a common event in both copy number-driven and translocation-driven soft tissue sarcoma but not bone sarcoma subtypes. Except for embryonic rhabdomyosarcoma, high levels of CD163+ M2 macrophages have been associated with unfavorable outcome [116]. In addition to macrophages, soft tissue sarcomas are dominated by B lymphocytes. A recent study showed that the high presence of B cells prior to neoadjuvant therapy correlates with better survival and response [117, 118]. Interestingly, other markers exhibiting a prognostic value as revealed by studies in carcinomas including tumor mutational burden and MSI, are dispensable for sarcomas. Particularly in soft tissue sarcomas, the tumor mutational burden is low and instability of microsatellites does not play a crucial role [119].

Thus, treatment decisions based on a single analyte most likely fail to capture the complete picture of the dynamic immune microenvironment leading to individuals undergoing unnecessary treatments. To this end, first efforts to develop immune-related signatures from responders including data from different clinical studies along with a scoring algorithm predicting response to ICI therapy have been already made while others are currently underway [120-123].

Hypoxia

In agreement with other solid malignancies, sarcomas are defined by a leaky and fragile vascular-structure which impedes proper tissue oxygenation and nutrient delivery. To compensate for nutrient and oxygen scarcity, tumor cells trigger the HIF signaling pathway and consequent expression of pro-angiogenic proteins, such as vascular endothelial growth factor (VEGF), angiopoietin-1/-2, platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF). HIF-1α is the transcriptional activator of CTLA-4 in CD8+ T cells and PD-L1 (encoded by the CD274 gene) in tumor cells and various types of immune cells, such as MDSCs, macrophages, DCs, and bone marrow-derived macrophages [124]. HIF-1α may also regulate the expression of PD-L1 through the activation of carbonic anhydrase 9. Carbonic anhydrase 9 causes tissue acidosis in the tumor stroma and the low pH, in turn, inhibits the cytotoxic function of CD8+ T cells and IFN production by Th1 cells. Hypoxia may also upregulate PD-1, CTLA-4 and TGF-β expression on the surface of T cells through the adenosine (Ado-A2aR) pathway which further promotes immune tolerance by diverting the cytokine and cellular profile of the TME away from cytotoxic T cell inflammation, leading to tumor progression and metastasis [125]. Suppression of adenosine pathway using the CD73 inhibitor plus the ICI, durvalumab,
under evaluation in a phase 2 trial for the treatment of recurrent, refractory or metastatic sarcoma (NCT04668300). VEGF is considered the master regulator of tumor angiogenesis serving to increase endothelial cell proliferation, survival and migration, while promoting vessel permeability. In addition to their pro-angiogenic functions, VEGF and FGF drive endothelial cell anergy by downregulating the adhesion molecules on vessel walls required for T cell homing [126]. HIF1α, VEGFs and VEGFRs are upregulated in at least 25% of sarcomas and their expression is linked with advanced tumor stage and poor prognosis [127, 128]. Pazopanib is a VEGFR inhibitor approved for the treatment of chemotherapy-refractory sarcomas. Nevertheless, the responsiveness of sarcoma patients to pazopanib is limited to specific subtypes and does not always lead to improved clinical benefit in combination treatments, although preclinical data seemed promising. For example, pazopanib does not improve progression free survival of patients with advanced angiosarcomas when combined with carotuximab to improved clinical benefit in combination promising. For example, pazopanib aggressiveness via transcriptional regulation of (TRC105), a TGFβ co-receptor and essential for angiogenesis [129].

In addition to the aberrant genomic instability caused by alterations in DNA repair pathways and release of free radicals, hypoxia promotes tumor aggressiveness via transcriptional regulation of downstream targets that sustain tumor aggressiveness and low immune cell infiltration [130]. Recent preclinical findings indicate that transcriptomic response to hypoxia is well preserved across soft tissue sarcoma cell lines and agrees with the published gene signatures [130]. The influence of hypoxia on many aspects of the TME pathophysiology explains why the first attempts of antiangiogenic treatment to completely shut down tumor vessels failed [131]. Instead, lower doses of anti-VEGF therapy have been more successful in normalizing the tumor vasculature, increasing perfusion and enhancing T cell infiltration, suggesting that the judicious use of antiangiogenic agents is a promising strategy for cancer treatment [132]. Nowadays, different clinical trials are investigating the combination of anti-angiogenic drugs with ICI in patients with different types of cancers, including alveolar soft part sarcoma, showing promising results [133-137].

The hypoxic stroma might be also exploited to activate prodrugs. For example, the hypoxia-activated prodrug TH-302 was found to significantly reduce hypoxia in a preclinical mouse prostate model while its combination with ICLs cured more than 80% of tumors by restoring T cell infiltration and reducing MDSCs [138]. The apparent potential of TH-302 prodrug is currently evaluated in a phase 2 trial in combination with doxorubicin for patients with advanced soft tissue sarcoma (NCT01440088).

**Immunosuppressive extracellular matrix (ECM)**

Another barrier of the TME that restricts infiltration of lymphocytes is the strong expression of mesenchymal and collagen barrier molecules in the ECM. In tumors, the ECM can undergo structural rearrangements to support tumor growth, including the production of collagen-driven fibrosis, a hallmark of many desmoplastic tumors [139]. CAFs are the major source of collagen synthesis and most abundant cell population in the TME. They may coexist as a heterogeneous population characterized by distinct phenotypic markers, gene expression profile and functionality [140]. Traditionally CAFs have been associated with aggressive behaviors and immune suppression. For instance, release of IL6 by CAFs promotes the differentiation of Tregs and IL17-producing T helper (Th17) cells [141, 142]. Indeed, Th17 T cells possess both anti- and pro-tumor responses [143]. On one side they recruit CD8+ T cells to the TME, while on the other, they release IL17 inducing the production of angiogenic factors from fibroblasts and cancer cells. Moreover, the direct interaction with T cells via the cell surface ligands displayed by CAFs prevents their trafficking within the TME. Adding to this, MHC-I-antigen presentation by CAFs combined with PD-L2 and FASL expression on the CAF cell surface, can result in killing of antigen-specific cytotoxic CD8+ T cells.

Unlike epithelial cancers, the current understanding of the origin and contribution of CAFs in sarcomas is very limited. Studies in Ewing sarcoma [144] and osteosarcoma [145] have demonstrated that extracellular vesicles and associated cargo secreted from tumor cells drive the transformation of normal fibroblasts into CAFs. On the contrary, rhabdomyosarcoma cells do not rely on CAFs to prime the ECM for local tumor expansion, but rather produce their own ECM with minimal involvement of CAFs [146]. Other preclinical studies support that the transition of gastric resident fibroblasts to CAFs is mediated by TGFβ signaling, promoting cancer metastasis in gastrointestinal stromal tumor [147]. CAFs may also promote immunosuppression via the CXCL12/CXCR4 and IL6/STAT3 signaling pathways. Osteosarcoma patients with high levels CXCL12 in CAFs have better overall survival [148], and CXCL12 targeting can enhance the sensitivity of these tumors to immunotherapy [149].
Figure 2: A. Immune phenotypes of solid tumors and normalization strategies. Based on the spatial distribution of CD8+ T lymphocytes in the TME, solid tumors are classified into highly inflamed- “hot” and non-inflamed- “cold”. “Cold” tumors like Ewing sarcoma can be further subdivided into immune desert or immune excluded. In “hot” tumors like most soft tissue sarcomas and osteosarcoma, T cells are present but inactive or exhausted. TME of “hot” tumors is defined by PD-1+ T cells and PD-L1+ tumor cells and macrophages, a high degree of tumor mutational burden and generally correlates with good response to ICI. In the immune desert phenotype, immune cells are absent from the tumor and its periphery while in the immune-excluded phenotype, immune cells accumulate at the periphery and do not efficiently infiltrate tumor bed. B. These three immune phenotypes can be reverted by TME normalization. TME normalization can be achieved by normalization of the tumor vasculature through targeting of angiogenic factors (such as VEGF and/or angiopoietin-2) and/or immune checkpoints (PD-L1, PD-1) and by normalization of the tumor ECM including reprogramming of CAFs to reduce fibrosis. These two normalization strategies either alone or in combination improve vessel perfusion, oxygen delivery, infiltration and activation of T cells and drug distribution.

Mesenchymal stem cells (MSCs)

While there is not a single cell origin ascribed to all sarcomas, increasing evidence suggests that MSCs are the sarcoma-initiating cells. MSCs are multipotent stem cells that differentiate towards diverse cell types including adipocytes, osteocytes, neural cells, fibroblast, chondrocytes and skeletal myoblasts. Several studies suggest that sarcomas arise from the malignant transformation of primitive MSCs or progenitor cells and many share a similar gene signature with the differentiated state of MSCs, possibly explaining the heterogeneity of these cancers. Although MSCs correspond to a small fraction of cells within the TME, yet they have a critical role in shaping the TME by promoting stemness, epithelial to mesenchymal transition, enhancing aggressiveness and drug resistance. It is very likely that resident tumor MSCs are responsible for relapse and metastasis. In osteosarcoma, the acidic microenvironment activates MSCs by inducing clonogenicity and invasion [150]. Such induction, triggers MSCs to undergo aerobic glycolysis (Warburg effect) and subsequent production of lactate, the main driver of tumor acidosis. Besides fueling the tumor, in vitro findings demonstrate that MSCs stimulate osteosarcoma cells to express pro-angiogenic factors that promote the formation endothelial capillaries. Of course, MSCs have distinct immunomodulatory properties. Various studies have reported that they may sustain tumor progression by inhibiting T cell proliferation and activation, suppressing the cytotoxic
activity of NKs, redirecting macrophages towards the immunosuppressive M2 phenotype and promoting regulatory T cell differentiation. In addition, MSCs inhibit B cell proliferation and antibody production [151].

**Metabolic barriers**

Stroma acidification is another essential aspect of sarcoma microenvironment impeding immunotherapy. The limited delivery of serum nutrients and hypoxia push cancer cells to adopt alternative metabolic routes to cope with the high energetic demand for proliferation and survival. The catabolism of glucose via aerobic glycolysis is one primary metabolic adaptation that cancer cells undertake. However, a significant fraction of pyruvate is converted into lactic acid and secreted from the cell. Accumulation of lactic acid and other metabolic waste products in the TME impairs the function of immune cells inhibiting T cell proliferation and IFNγ production and thus, compromising the effector function of CD8+ T cells and NK cells. Furthermore, lactic acid inhibits monocyte activation and DC differentiation, promotes M2-polarization via increased arginase and HIF1α stabilization and increases the number of MDSCs. Finally, it may enhance the survival of Tregs, given the ability of Tregs to metabolize oxidized exogenous lactate. Many pediatric tumors including osteosarcoma and Ewing sarcoma have upregulated glycolysis and lactic acid fermentation. In fact, the oncogenic fusion protein EWS/FLI1 present in 80% of Ewing sarcoma cases, is the key regulator of the aberrant glycolytic reprogramming of cancer cells [152]. Moreover, high glycolytic flux and upregulated expression of lactate dehydrogenase, the enzyme that catalyzes the conversion of lactate to pyruvate and back, was found to associate with doxorubicin resistance in chondrosarcoma cell lines [153]. Acidification as a mechanism of chemoresistance was also confirmed in osteosarcoma and rhabdomyosarcoma cell lines, where doxorubicin and other weak base drugs are trapped inside the highly acidic lysosomes due to an aberrant ion pumping (ion trapping mechanism) and consequently cannot target cancer cells [154]. Although lactate-responsive pathways may offer opportunities to increase the efficacy of immunotherapy across diverse tumor types, it is important to consider that each of these targets is TME-context and immune cell specific and therefore lead to contradictory effects on immune cell function. Accordingly, neutralization of low pH may have a meaningful impact on improving the efficacy and outcomes of anticancer immunotherapy.

Depending on the cell type and environmental conditions the products of glycolysis can be utilized to produce nucleotides or enter the mitochondrial tricarboxylic acid cycle (TCA) cycle which in turn will provide the metabolic intermediates required for biosynthesis of lipids and amino acids. However, decreased entry of glucose into the TCA cycle combined with the shuttling of intermediates into the biosynthetic pathways, imposes a need for TCA anaplerosis with an alternative carbon source other than glucose. The most common carbon source involved in TCA anaplerosis is the glutamine.

Unlike glucose, which is required for both cancer and immune cell growth, glutamine is differentially utilized by each of these populations. Interestingly, inflammatory anti-tumor immune cells like M1 macrophages have less dependency on glutamine metabolism compared to M2 which rely on glutaminolysis for expansion. Also, studies in undifferentiated pleomorphic sarcoma showed that these cancer cells largely rely on glutamine as a source of energy and biosynthetic anabolism. Targeting of glutamine metabolism has been recently explored in preclinical models of undifferentiated pleomorphic sarcoma and additional soft tissue sarcoma subtypes showing encouraging results [155].

In addition to glutamine, cancer cells consume large quantities of arginine and tryptophan amino acids to support their growth and promote immune tolerance. Arginine is a crucial conditional amino acid for both cancer and immune cells. Arginine metabolism relies on the activity of arginase and inducible nitric oxide synthase (iNOS). Lactic acid abundance in TME favors the catabolism of arginine in myeloid cells via the arginase over iNOS, resulting in increased secretion of tumor-supporting factors by TAMs. On the contrary, TAMs utilizing iNOS exhibit an M1 phenotype and their nitric oxide upregulates the expression of VCAM1 adhesion molecules and subsequent T cell extravasation and homing against tumors. Importantly, CD8+ T cells benefit from L-arginine uptake by enhancing survival, memory formation and anti-tumor efficacy. Different primary sarcomas like osteosarcoma, Ewing sarcoma and rhabdomyosarcoma were reported to have lost or lack the ability to synthesize arginine de novo (arginine auxotrophic) and highly depend on extracellular arginine in TME [156, 157]. Preclinical studies on animal models have demonstrated that combination therapy with L-arginine and anti-PD-L1 antibody boosts immune response against osteosarcoma [158]. It should be mentioned that depletion of arginine in sarcoma patients either alone (NCT03455140) or in combination with gemcitabine and decotaxel (NCT03449901) is already exploited in clinic showing positive results [159]. Its synergistic effects with
immunotherapy, though, are yet to be determined in the clinical setting.

As opposed to glutamine and arginine, tryptophan is an essential amino acid which must be taken from the diet. Tryptophan acts as a substrate for kynurenine pathway. In tumors, however, increased levels of indoleamine 2,3-dioxygenase (IDO) catabolic enzymes (e.g., IDO1) deplete tryptophan from TME and promote the production of immunosuppressive kynurenine metabolites. Increased IDO1 activity prevents activation of effector T cells, inhibits NK function and supports Treg differentiation and MDSCs infiltration. Despite clinical trials using IDO inhibitors have so far led to disappointing results, combinations with anti-PD-1 improved the objective response rates in melanoma patients. Given the fact that IDO1 is highly expressed on Ewing sarcoma cells and has been associated with worse outcome in osteosarcoma, among other cancers [160, 161], combining such IDO inhibitors with immunotherapy may provide significant therapeutic benefit for those patients. In the case of STS, preclinical and clinical application of IDO inhibitors did not confer any significant benefit to anti-PD-L1 treatment, which patients. In the case of STS, preclinical and clinical application of IDO inhibitors did not confer any significant benefit to anti-PD-L1 treatment, which slightly improved survival compared to untreated control in a model of murine fibrosarcoma [162]. These data may explain in part the clinical failure of PD-L1 inhibition in selected soft tissue sarcomas and gastrointestinal stromal tumors as a consequence of immunosuppressive TME resulting from macrophage infiltration and IDO1 pathway activation [163].

Strategies to overcome barriers to sarcoma immunotherapy

We have thus far discussed the current progress in immunotherapy for the treatment of soft tissue and bone sarcoma with emphasis on the barriers impeding its antitumor activities. It appears that the high metabolic rate of cancer cells in conjunction with the poor vascularization and the limited nutrient exchange lead to a fierce competition for resources. In a TME deprived from amino acids and glucose, T cells fail to substantially increase their nutrient or engage the appropriate metabolic pathway, required to mount proper immune responses. In an effort to overcome these challenges, research has in part focused on reprogramming the TME as a promising approach for increasing the efficacy of many therapeutic agents, ranging from standard chemotherapeutics to nanomedicine and immunotherapy modalities. TME can be reprogrammed (i.e., normalized) both at the vascular and stromal level, so that it morphologically and functionally resembles the non-malignant state of the tissue [164-166] (Figure 2B). As such, TME reprogramming aims to improve tumor perfusion and treat hypoxia by normalizing either the abnormal structure of the tumor vessels or tumor stromal components. Of note, a recent phase 1b/2 trial (ImmunoSarc) indicated that inhibition of angiogenesis via sunitinib plus nivolumab is an active regimen with manageable toxicity in the treatment of selected patients with advanced soft tissue sarcoma with almost half of patients being free of progression at 6 months [167]. Furthermore, preclinical studies on murine osteosarcoma models demonstrated that combination of sunitinib with PD-L1 blockade reduced the expression of PD-L1 by suppressing STAT3 activation, and thus inhibiting lung metastases, tumor growth which in turn improved survival [168].

Stromal normalization/reprogramming

Nevertheless, application of antiangiogenic drugs does not impact perfusion of tumors with extremely compressed vessels, such as many sarcoma and pancreatic adenocarcinoma types, consistent with poor clinical response [169, 170]. Vessel compression is independent from changes occurring in angiogenesis. It arises, though, from the excessive accumulation of mechanical forces generated by the rapid proliferation of tumor cells and CAFs within the confined space of the host tissue, a condition known as solid stress [171]. Solid stress can be stored in ECM and the surrounding host tissue structural components and then transmitted to tumor vasculature [172]. Accordingly, tumor stroma normalization/reprogramming strategies focus on targeting these ECM barriers, such as collagen, and the immediate environment allowing vessel decompression, reduction of tissue stiffness and improved intratumoral penetration of drugs and immune cells [171, 173]. It is worth mentioning that depletion rather than reprogramming of ECM components besides contributing to stress alleviation it may increase the risk for disease progression [174].

Molecules with tissue reprogramming capabilities are known as “mechanotherapeutics” [175]. Mechanotherapeutics refer to a subset of TME normalization therapies targeting the mechanical microenvironment (i.e., tumor stiffness and solid stress) in order to improve perfusion and alleviate hypoxia. Successful examples of mechanotherapeutics include common hypertensive drugs (e.g., losartan [176, 177]), antihistamines (e.g., tranilast [178, 179]), anti-diabetic drugs (e.g., metformin [180]), anti-inflammatory drugs (e.g., dexamethasone [181], pirfenidone [182]), endothelin receptor antagonists (e.g., bosentan [183]), antifibrotic agents (e.g., vitamin D receptor agonists [184], pentoxyfylline [185], relaxin [186, 187]). In line with these studies, our recent
findings in preclinical models of fibrosarcoma and osteosarcoma indicate that the antihistamine drug ketotifen not only inhibits ECM formation but also potentiates anti-PD-L1 immunotherapy by reverting the immunosuppressive TME and increasing overall survival. Significantly, combination therapy with anthracycline drugs (doxorubicin or epirubicin) show therapeutic superiority as opposed to anthracycline-anti-PD-L1 or anthracycline-ketotifen treatment, offering a durable remission and immunological memory. These therapeutic effects correlate well with a reduction in tumor stiffness and increase in vascular perfusion, suggesting that TME priming with such mechanotherapeutics is a prerequisite to creating favorable immunogenic conditions capable of eliminating the entirety of tumor and thus, providing a significant rational for clinical translation [188, 189].

Another mechanotherapeutic approach holding great promise in potentiating immunotherapy is the targeting of TGFβ signaling pathway. TGFβ signaling is abnormally upregulated in most cancers and widely associated with tumor growth and progression. TGFβ is expressed by cancer cells, DCs, macrophages, CAFs and immature myeloid cells, indicating functional divergence. Its role in CAFs has been linked to immunosuppressive responses via attenuation of tumor response to PD-L1 blockade and contributing to T cell exclusion [190] and by driving immune evasion [191, 192]. Inhibition of TGFβ in mouse tumor models has been shown to trigger potent T cell responses [191], upregulate the expression VCAM-1 and ICAM-1 adhesion molecules [193] and promote the abscopal effect of radiotherapy [194]. Specific downstream targets of TGFβ that contribute to this effect include NOX4 [195] and CXCL12/CXCR4 pathway [196]. Clinical exploitation of mechanotherapeutics in sarcoma immunotherapy has lagged behind that of other solid malignancies. Nonetheless, emerging preclinical data support that genetic ablation of TGFβ signaling specifically in NKp46+ cells could decrease the frequencies of intILC1 and ILC1 populations, which have been associated with immune suppression, in fibrosarcoma TME [197]. In line with these results, pharmacological blocking of TGFβ receptor could restore immune suppression induced by regulatory B–T cell axis and decrease tumor burden in murine fibrosarcoma [198]. A different study on osteosarcoma reported that vaccination with DC exposed to cryotreated tumor lysates combined with anti-TGFβ antibody increased CTLs and reduced regulatory T lymphocytes in the metastatic lesion mediating inhibition of metastatic growth [87]. Accordingly, combining TGFβ blockade with ICI and other immunotherapy modalities is an attractive strategy to induce complete and durable responses in otherwise unresponsive soft tissue and bone sarcoma tumors.

### Potential of Nanomedicine to treat sarcoma and remodel the TME

Nanomedicine has improved therapeutic index and quality of life for sarcoma patients. DaunoXome® and Doxil® - liposomal formulations of daunorubicin and doxorubicin, respectively - were the first nanomedicines to be approved for the treatment of HIV-related Kaposi’s sarcoma [199, 200]. Later advances in nanotechnology led to the development of nab-paclitaxel (Abraxane®), a nanoparticle albumin-bound paclitaxel, which is a new type of taxane antineoplastic drug and has been indicated for the treatment of metastatic breast cancer, non-small cell lung cancer and metastatic pancreatic cancer [201]. Evidence shows that nab-paclitaxel has promising effects in the treatment of angiosarcoma, epithelioid sarcoma, leiomyosarcoma, and other subtypes of soft tissue sarcomas [202] and can be safely combined with gemcitabine or receptor tyrosine inhibitors for an improved curative effect [203, 204]. On the other hand, nanomedicine-immunotherapy combinations remain poorly investigated in sarcomas. To date, the safety and tolerability of nivolumab plus albumin-bound rapamycin (ABI-009) is evaluated in a phase 1/2 trial for advanced Ewing sarcoma and epithelioid sarcoma among other solid malignancies (NCT03190174). Irinotecan (NCT02013336), vincristine (NCT00038207) and epirubicin (NC6300, NCT03168061) encapsulated nanoparticles, are under clinical evaluation for the treatment of pediatric sarcomas and advanced solid tumors or advanced, metastatic, or unresectable soft tissue sarcoma, respectively. As therapeutic carriers, they have many advantages over conventional drug administration, including improved pharmacokinetic properties, prolonged circulating half-lives and sustained and controlled load release at the tumor site. The preferential accumulation at the tumor site is mediated through the enhanced permeability and retention (EPR) effect, which has been the key rational for the development of nanoparticle-based delivery systems [205-207]. However, EPR heterogeneity between patients and tumor types may pose a barrier itself and hinder efficacy of nanomedicines. Furthermore, the enhanced permeability of tumor vessels that can cause an excessive fluid loss to the interstitial space and the impaired lymphatic drainage elevate the interstitial fluid pressure. As a result, interstitial fluid pressure becomes comparable to the microvascular pressure and diffusion becomes the main mechanism of nanoparticle transport across the
tumor vessel walls, which does not favor the delivery of large therapeutic agents [208-210].

An emerging strategy to optimize the benefits of the EPR effect is by normalizing the TME, which results in reduction of interstitial fluid pressure without affecting tumor vessel hyperpermeability. With respect to this, we have shown that administration of nanomedicines in a metronomic fashion, defined as the frequent, low dose administration compared to the maximum tolerated dose at long time intervals, can normalize the TME. Although not clinically approved yet, our preclinical findings demonstrate that the metronomic administration of Doxil® in mice bearing fibrosarcoma tumors yields improved anti-tumor effects than the conventional maximum tolerated dose schedule [211]. In addition to its cytotoxic function, metronomic Doxil® normalizes the TME, making the tumors softer, increasing perfusion and reducing interstitial fluid pressure and thus, overcoming the pathophysiological barriers to nanoparticle delivery. As a result of these normalization effects, combination of ICI with Doxil® can revert immunosuppression and improve ICI efficacy [211].

Nanoparticle formulations could be further employed to normalize the TME by encapsulation of mechanotherapeutic agents that preferentially target the tumor. In this regard, nanomedicines designed to simultaneously target components of the TME and kill cancer cells can be used to broaden the therapeutic window of anticancer drugs. The development of drug delivery systems incorporating angiotensin receptor blockers as mechanotherapeutics conjugated to polymers that can be selectively degraded in the TME upon exposure to low pH is such an example [212, 213]. Micellar formulations encapsulating the antihistamine tranilast have been also recently developed [214].

**Imaging techniques for monitoring TME burden**

Several non-invasive imaging modalities can be employed for monitoring intratumoral drug distribution and efficacy, such as ultrasound imaging, magnetic resonance imaging (MRI), computed tomography (CT), Positron Emission Tomography (PET), single photon emission computed tomography (SPECT) and optical imaging [215]. CT, MRI and ultrasound techniques allow the cross-sectional 3D visualization of the tissue and are frequently employed in the clinic to provide anatomical information to assist tumor staging and therapy monitoring. Furthermore, many of these imaging modalities can be used to image components of the TME related to the barriers of drug delivery, including tumor perfusion, hypoxia and vascular permeability. Specifically, PET allows for the use of specific radiotracers for measuring hypoxia, proliferation and angiogenesis, whereas contrast-enhanced CT and ultrasound methods have been employed to quantify tumor perfusion and the efficacy of the tumor micro-vasculature to effectively deliver drugs [216-219]. In addition, MR and ultrasound can provide information of the stiffness of the tissue (i.e., MR elastography and shear wave elastography), which is directly related to tumor perfusion, and MRI can further measure the permeability of the tumor vessels [183, 214, 220]. Given that tumor hypo-perfusion is a major barrier to the effective delivery of drugs and that normalization therapeutic strategies have been developed to restore the TME and thus, improve perfusion and drug efficacy, these imaging modalities can be employed to guide and monitor normalization treatments to optimize delivery of medicines, including immunotherapeutics [183, 214].

**Nano-immunotherapy reinforces the cancer immunity cycle**

Combining nanomedicine with immunotherapy aims to reinforce key steps of the cancer immunity cycle (Figure 3 and Refs [221-223] for a detailed review of this topic). Firstly, cancer nanomedicines can be utilized to deliver cytotoxic chemotherapy agents capable of inducing the release of tumor antigens and eliciting immunogenic cell death (step 1, Figure 3). The clinical potential of combining Abraxane® with the PD-1 inhibitor atezolizumab has already been demonstrated in a phase 3 clinical trial for the treatment of triple negative breast cancer and in a retrospective study of soft tissue sarcoma, with angiosarcoma patients reporting a significantly prolonged free survival compared to other subtypes [224]. Doxil®, similarly to Abraxane®, induces immunogenic cell death by promoting immune cell infiltration and reverting tumor immunosuppression [225]. A second strategy to integrate nanomedicine in the cancer-immunity cycle is by potentiating the antigen uptake, processing and presentation with the use of adjuvants (step 2-3, Figure 3). Targeted delivery of Toll-like receptor agonists to antigen presenting cells in secondary lymphoid organs can boost their anti-tumor immune responses while minimizing severe side effects associated with adjuvant therapy. Adding to this, nanocarriers can be utilized to deliver cytokines (e.g., IL2) to stimulate and expand T cell population [221]. Finally, nanomedicine can be utilized as a co-treatment to prime the TME for improved efficacy of immunotherapy modalities. As discussed above, such nanomedicines may
incorporate mechanotherapeutic agents and their added value in this regard is related to their ability to normalize the TME, revert the immunosuppressive phenotype of TAMs and promote immune activation. In a prospective randomized phase 3 trial for the treatment of osteosarcoma, the combination of the immune modulator, liposomal muramyl tripeptide phosphatidylethanolamine, with a three-drug chemotherapy regimen (doxorubicin, cisplatin, methotrexane) demonstrated a trend of improved overall survival for the patients who received the liposomal nanoparticle in addition to chemotherapy regimen [226]. However, the study was not adequately powered to make firm conclusions.

**Adverse effects of immunotherapy**

Immunotherapy advances, despite their promise, are often associated with immune related...
adverse events (irAEs), as a consequence of the nonspecific immune activation in the human body. irAEs differ from the classical chemotherapy-induced toxicities and may occur in almost any organ such as colon, muscle, lungs, liver and thyroid. Their frequency depends on the dosage, regimens and exposure time but also on patient’s intrinsic factors. A few studies have specifically assessed the safety of ICI in patients with recurrent or therapy refractory sarcomas. A phase 1 dose escalation study (NCT01445379), investigating the tolerance and toxicity profile of ipilimumab monotherapy in children and young adults indicated that the occurrence of high grade irAEs associates with better response to CTLA-4 inhibition, although a proportional increase in the frequency of irAEs was observed with an increase in dose level. A different study assessing the safety of nivolumab as monotherapy (ADV11412, NCT02304458) showed that administration of 3 mg/kg every 14 days is well tolerated in children with Ewing, rhabdomyosarcoma, and osteosarcoma subtypes and the most common irAEs reported were: increased lipase levels and cardiac and pleural effusion. In the SARC028 (NCT02301039) study, the most frequent grade 3 or worse adverse effect reported in both bone and soft tissue sarcoma groups was anaemia, followed by decreased lymphocyte count and prolonged activated partial thromboplastin time. Also, some patients of the bone sarcoma group had decreased platelet count. Notably, none of these treatment-related serious adverse events were fatal. Alliance (A091401, NCT02500797) [27] is another study investigating tolerability of nivolumab with or without ipilimumab. The dose and schedule for the combination tested (3 mg/kg nivolumab plus 1 mg/kg ipilimumab) had acceptable toxicity, with 14% of patients having grade 3 or 4 treatment-related adverse events. Similar to other studies, anaemia and decreased lymphocyte count were the most frequent adverse effects reported among patients. Additional irAEs reported were dehydration, increased lipase, pain, pleural effusion, respiratory failure, secondary benign neoplasm, and urinary tract obstruction.

In general, the incidence of fatal irAEs for ICI not only for sarcomas but among all tumor types ranges between 0.3% and 1.3%, which is lower compared to conventional treatments. A meta-analysis by Wang et al. in 2018 [227] indicated colitis for CTLA-4 inhibitors (70%, 135/193 deaths), pneumonitis (35%, 115/333 deaths) for PD-1 or PD-L1 inhibitors, and colitis (37%, 32/87) for the combination PD-1 and CTLA-4 inhibition as the most frequent causes of death as an irAE. Less life-threatening irAEs including rash, pruritus and vitiligo have been reported in more than one-third of the patients [227]. However, this study failed to provide data about the incidences of low-grade and high-grade adverse events and included only a limited number of sarcoma patients and thus, may did not recapitulate the extend of fatal ICI-associated toxic effects. Accordingly, a more comprehensive analysis aiming to compare organ-specific irAEs of ICI monotherapy versus combination among patients of the same cancer is essential for clinicians to balance the benefits and risks of ICI during treatment [228].

Conclusion

Undoubtedly, the limited number of patients, the high interpatient heterogeneity and the lack of specific markers expressed by most sarcoma cells contribute to the limited advances in the field of immunotherapy. Consequently, it is not surprising that the clinical success of ICI results in sporadic therapeutic responses in sarcoma. Combination treatments have been employed instead to overcome these challenges. As described earlier, several preclinical studies indicate that the future of immunotherapy relies on the combination with conventional chemotherapeutics and radiotherapeutics or the combination of two or more different immunotherapy modalities. Although such combinatorial treatment schemes manage to accentuate the effect in most sarcoma subtypes, the reported influence on complete response and progression free survival remains minimal. Given that ICI normalization of the TME alleviates hypoxia towards increasing efficacy of immune checkpoint inhibition, it may worth exploring the impact of “mechanotherapeutics” as means to increase the quality and magnitude of immunotherapy modalities. In line with this, accumulating evidence indicates that targeting of fibrosis by suppressing CAFs not only influences the de novo immune responses but dictates the success of immunotherapies as well. Supported by the stiff ECM, CAFs interact with cancer cells to convey metabolic signals required for cancer cell glycolysis, increased catabolic activity and autophagy. Meanwhile, the rapid consumption of available nutrients by cancer cells and secretion of lactate, create regions of hypoxia and high acidity, which further hinder immune cell function. Importantly, T cells found in hypoxic areas of inflamed sarcoma tumors exhibit a profound mitochondrial dysfunction and lack of cytokine production until after checkpoint blockade, suggesting that antigen recognition and infiltration into tumors alone are insufficient for an antitumor response and that the metabolic TME can directly suppress T cells. However, direct targeting of the hypoxia-sensing pathway, HIF, is not immune specific and thus, it may have conflicting effects on
the function of CTLs and anti-tumor therapies. Likewise, metabolic pathways with distinct dependencies on cancer and pro-inflammatory immune cells and macrophages must be exploited to achieve a multi-pronged approach for cancer therapy. While “mechanotherapeutics” alone do not possess any antitumor effects, their application lies on targeting the tumor-induced vasculature and ECM that hamper T cell migration and effector function of resident cells, as such allowing efficient priming of TME for an effective antitumor immune response. Thus, their role although complementary is rather crucial for T cell activation of T cells and suppressing the immune tolerance. It is expected that upcoming studies employing TME normalization strategies will be focused on the stratification and selection of patients based on the immune phenotype (i.e., immune deficit, immune excluded or immune inflamed) (Figure 3) and metabolic adaptations. These immune phenotypes reflect tumors at different phases of the seven-step cancer-immunity cycle which must be completed repeatedly in order for immunotherapies to be effective. TME normalization can enhance each step of the cancer-immunity cycle and promote its perpetuation.

With respect to future directions, convergence of artificial intelligence and precision medicine offers a breakthrough in biomarker research and disease diagnosis. Indeed, in sarcomas there is not “one-size fits all” molecular target and each subtype needs to be studied independently. This underlines the need for elaborating new minimally invasive techniques to monitor patient progress at a given time like high-throughput molecular profiling. An ongoing clinical trial, MULTISARC (NCT03784014), assesses the feasibility of next generation sequencing exome in metastatic soft tissue sarcoma patients to identify actionable mutations. Under clinical investigation is also the development of conserved transcription signatures spanning sarcoma subtypes including the Complexity Index in Sarcomas (CINSARC), hypoxia associate signature and genomic grade index [229]. The next step will be to integrate the information obtained from clinical cohorts and preclinical studies in sarcoma cell lines, patient derived samples and tumor models to improve prediction of response to therapy. Assessment of circulating tumor cells, cell-free circulating DNA, tumor derived extracellular vesicles and metabolomic profiling could complement the immunohistochemistry data and assist the genomically guided lines of treatment. Precision medicine relies on the ability to integrate high throughput molecular and computational data to increase the accuracy of diagnosis, prognosis and to identify the most effective therapy.

Supplementary Material

Acknowledgments
This project received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreements no. 863955 and 101069207) to T.S.

Competing Interests
The authors have declared that no competing interest exists.

References
20. Suzman DL, Agraval S, Ning Y, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial...


266. Romero I, Garrido C, Algarra I, et al. MHC intratumoral heterogeneity may
278. Rainusso N, Brawley VS, Ghazi A, et al. Immunotherapy targeting HER2 with
264. van Hooren L, Georganaki M, Huang H, et al. Sunitinib enhances the
265. Walker JM, Rolig AS, Charych DH, et al. NKTR-214 immunotherapy
256. Tu MM, Lee FY, Jones RT, et al. Targeting DDR2 enhances tumor response to
254. Tu MM, Lee FY, Jones RT, et al. Targeting DDR2 enhances tumor response to
246. Li Q, Hao Z, Hong Y, et al. Reprogramming tumor associated macrophage
244. van Hooren L, Georganaki M, Huang H, et al. Sunitinib enhances the
242. Tu MM, Lee FY, Jones RT, et al. Targeting DDR2 enhances tumor response to
240. Tu MM, Lee FY, Jones RT, et al. Targeting DDR2 enhances tumor response to
239. Yao Z, Qian J, Wu J, et al. Milagenguc mRNA-based electrotransfection of
237. Evans CH, Liu F, Porter RM, et al. EWS-FLI-1-targeted cytotoxic T cell killing of
230. Tu MM, Lee FY, Jones RT, et al. Targeting DDR2 enhances tumor response to
229. Tu MM, Lee FY, Jones RT, et al. Targeting DDR2 enhances tumor response to
226. van Hooren L, Georganaki M, Huang H, et al. Sunitinib enhances the
223. van Hooren L, Georganaki M, Huang H, et al. Sunitinib enhances the
222. van Hooren L, Georganaki M, Huang H, et al. Sunitinib enhances the
218. van Hooren L, Georganaki M, Huang H, et al. Sunitinib enhances the
216. van Hooren L, Georganaki M, Huang H, et al. Sunitinib enhances the
214. van Hooren L, Georganaki M, Huang H, et al. Sunitinib enhances the
212. van Hooren L, Georganaki M, Huang H, et al. Sunitinib enhances the
210. van Hooren L, Georganaki M, Huang H, et al. Sunitinib enhances the
209. van Hooren L, Georganaki M, Huang H, et al. Sunitinib enhances the
208. van Hooren L, Georganaki M, Huang H, et al. Sunitinib enhances the
207. van Hooren L, Georganaki M, Huang H, et al. Sunitinib enhances the
functions and therapeutically intervenes in the growth of mouse sarcoma.


